BetterLife Pharma Inc. (BETR.CN)

BetterLife Pharma Inc. (BETR.CN) — VMCI valuation read

BetterLife Pharma Inc. sits at VMCI 29/100, with the Healthcare sector median at 50. That 21-point spread is the first thing to note on BETR.CN: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on BETR.CN are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on BETR.CN: BETR.CN trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of -0.9x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

BETR.CN rose 3.6% over the trailing 7 days, with a +4.5% read on a 30-day basis.